{
    "Clinical Trial ID": "NCT00074152",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I",
        "  Observation (+/- Radiation). Patients receive radiotherapy* within 6 months after surgery.",
        "  radiation therapy: Given within 6 months after surgery",
        "INTERVENTION 2: ",
        "  Arm II",
        "  Chemotherapy (+/- Radiation). Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.",
        "  chemotherapy: Given within 10 weeks after surgery."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed invasive breast cancer",
        "  First local and/or regional (i.e., ipsilateral axillary or internal mammary lymph node region) recurrence after primary treatment with mastectomy or lumpectomy/quadrantectomy with clear surgical margins",
        "  Local failure is defined as a tumor recurrence in any soft tissue of the ipsilateral conserved breast or the chest wall, mastectomy scar, and/or skin",
        "  Regional failure is defined as a tumor recurrence in the ipsilateral axillary lymph nodes, extranodal soft tissue of the ipsilateral axilla, and/or ipsilateral internal mammary. Regional failure does not include supraclavicular lymph nodes or tumor in the opposite breast",
        "  No other prior recurrence in any site, including local",
        "  Surgical resection of the recurrence meeting 1 of the following criteria:",
        "  Uninvolved (\"clear\") margins and planned radiotherapy with at least 40 Gy for patients who had no prior adjuvant radiotherapy",
        "  Mastectomy of the recurrence with uninvolved (\"clear\") margins after lumpectomy/quadrantectomy alone for the primary",
        "  Adjuvant trastuzumab (Herceptin\u00ae) therapy or other HER-2 directed therapies are allowed for patients with HER-2 positive tumors and must be declared prior to randomization",
        "  No evidence of distant metastasis, including ipsilateral supraclavicular lymph nodes, by x-ray or CT scan of the chest, ultrasound or CT scan of the abdomen and pelvis, or bone scintigraphy only if alkaline phosphatase is > 2 times normal or if medically indicated (e.g., bone pain)",
        "  No macroscopically incomplete surgery",
        "  No bilateral malignancy except carcinoma in situ",
        "  No suspicious mass in the opposite breast unless that mass has been proven by biopsy to be benign",
        "  No skeletal pain of unknown cause",
        "  No hot spots on bone scan for which metastases cannot be ruled out by x-ray, MRI, and/or CT scan",
        "  Hormone receptor status:",
        "  Determined in the recurrent tumor by immunohistochemistry and/or ligand-binding assay",
        "  Estrogen receptor positive or negative",
        "  Progesterone receptor positive or negative",
        "  PATIENT CHARACTERISTICS:",
        "  Age",
        "  Minimum 18 years",
        "  Sex",
        "  Female",
        "  Menopausal status",
        "  Not specified",
        "  Performance status",
        "  Not specified",
        "  Life expectancy",
        "  Not specified",
        "  Hematopoietic",
        "  Not specified",
        "  Hepatic",
        "  No elevated alkaline phosphatase",
        "  Renal",
        "  Not specified",
        "  Other",
        "  Fertile patients must use effective non-hormonal contraception",
        "  Medically suitable for chemotherapy of 3-6 months duration",
        "  No other primary malignant tumors except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer",
        "  No non-malignant systemic disease that would preclude study treatment or prolong follow-up",
        "  No psychiatric or addictive disorder that would preclude giving informed consent",
        "  No history of noncompliance to medical regimens or potential for being unreliable",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy",
        "  Not specified",
        "  Chemotherapy",
        "  See Disease Characteristics",
        "  Endocrine therapy",
        "  Not specified",
        "  Radiotherapy",
        "  See Disease Characteristics",
        "  Surgery",
        "  See Disease Characteristics"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Disease-free Survival",
        "  [Not Specified]",
        "  Time frame: 5 years after randomization",
        "Results 1: ",
        "  Arm/Group Title: Arm I",
        "  Arm/Group Description: Observation (+/- Radiation). Patients receive radiotherapy* within 6 months after surgery.",
        "  radiation therapy: Given within 6 months after surgery",
        "  Overall Number of Participants Analyzed: 77",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  57        (44 to 67)",
        "Results 2: ",
        "  Arm/Group Title: Arm II",
        "  Arm/Group Description: Chemotherapy (+/- Radiation). Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.",
        "  chemotherapy: Given within 10 weeks after surgery.",
        "  Overall Number of Participants Analyzed: 85",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  69        (56 to 79)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/77 (0.00%)",
        "  Neutropenia  [1]0/77 (0.00%)",
        "  Left ventricular dysfunction 0/77 (0.00%)",
        "  Cardiac ischemia 0/77 (0.00%)",
        "  Gastrointestinal pain 0/77 (0.00%)",
        "  Colitis 0/77 (0.00%)",
        "  Febrile neutropenia 0/77 (0.00%)",
        "  Pulmonary/upper respiratory infection 0/77 (0.00%)",
        "  Diverticulitis 0/77 (0.00%)",
        "  Motor neuropathy 0/77 (0.00%)",
        "  Endometrial mucosa thinkening 0/77 (0.00%)",
        "Adverse Events 2:",
        "  Total: 12/85 (14.12%)",
        "  Neutropenia  [1]1/85 (1.18%)",
        "  Left ventricular dysfunction 1/85 (1.18%)",
        "  Cardiac ischemia 2/85 (2.35%)",
        "  Gastrointestinal pain 1/85 (1.18%)",
        "  Colitis 1/85 (1.18%)",
        "  Febrile neutropenia 3/85 (3.53%)",
        "  Pulmonary/upper respiratory infection 1/85 (1.18%)",
        "  Diverticulitis 1/85 (1.18%)",
        "  Motor neuropathy 1/85 (1.18%)",
        "  Endometrial mucosa thinkening 1/85 (1.18%)"
    ]
}